News Sentiment

TOI sentiment intelligence

Oncology Institute Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Care Facilities Read-through group
Latest close 5.89 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+11.6% over one week, +10.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

TOI (NASDAQ: TOI) plans sale of 23,452 shares worth $146,575.00

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 11.6% Price confirming higher
Trend fit Trend active 10.9% over four weeks
Fair value 186.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 31
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
simplywall.st 6
TradingView 5
GlobeNewswire 5
Market source 5
Investing.com Canada 3
Moomoo 3
Investing.com 3

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 8
Analyst action 7
Balance sheet 7
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
Stock Titan Direct company coverage

TOI (NASDAQ: TOI) plans sale of 23,452 shares worth $146,575.00

The Oncology Institute, Inc. (NASDAQ: TOI) has filed a Form 144 notice indicating a planned sale of 23,452 shares of common stock, valued at $146,575.00, through Morgan Stanley Smith Barney LLC Executive Financial Services. These shares were acquired on July 14, 2026, via an exer

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 20:41
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 The Oncology Institute For: 14 July By Investing.com

This article announces a Form 144 filing for The Oncology Institute, specifically for July 14th. The content is very brief, mainly serving as a headline for a financial market filing, with no further details provided within the article itself. It includes related stock market dat

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 20:41
Source
Investing.com Canada
GuruFocus Direct company coverage

Insider Buying: Jorey Chernett Acquires Additional Shares of The Oncology Institute Inc (TOI)

Jorey Chernett, a 10% Owner of The Oncology Institute Inc (TOI), purchased an additional 15,000 shares on July 10, 2026, increasing his total holdings to 10,630,858 shares. This purchase is part of a broader trend of insider buying for TOI, with Chernett having acquired 759,914 s

Tone
Negative 38/100
Event
Market update
Published
13 Jul 2026 18:40
Source
GuruFocus
Stock Titan Direct company coverage

Oncology Institute (TOI) major holder buys 15,000 shares in open market

Jorey Chernett, a major shareholder (over 10% owner) of Oncology Institute, Inc. (TOI), purchased 15,000 shares of common stock on July 10, 2026, for a weighted average price of $5.85 per share. This open-market transaction, detailed in a Form 4 filing, involved multiple trades w

Tone
Positive 92/100
Event
Market update
Published
13 Jul 2026 15:39
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Oncology Institute Inc For: 13 July By Investing.com

This article from Investing.com announces the filing of a Form 4 for Oncology Institute Inc on July 13. It includes general market data and related news articles, but provides no specific details about the Form 4 itself.

Tone
Positive 58/100
Event
Market update
Published
13 Jul 2026 15:39
Source
Investing.com Canada
Quartr Direct company coverage

The Oncology Institute (TOI) Proxy filing Summary

The Oncology Institute (TOI) has released a proxy filing summary detailing its upcoming annual meeting scheduled for June 17, 2026. Key items include the election of eight directors, the ratification of BDO as the independent public accounting firm for 2026, and advisory votes on

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 11:10
Source
Quartr
Stock Titan Direct company coverage

TOIIW SEC Filings - The Oncology Institute Inc 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for SEC filings related to The Oncology Institute Inc. (TOIIW), including 10-K, 10-Q, 8-K, and insider trading forms. Recent updates detail insider transactions by director Gabriel Ling, his resignation from the board, and a significant

Tone
Positive 61/100
Event
Market update
Published
10 Jul 2026 09:09
Source
Stock Titan
Moomoo Direct company coverage

Oncology Institute Price Target Raised to $9.00/Share From $8.00 by BTIG

BTIG has increased its price target for The Oncology Institute to $9.00 per share, up from the previous $8.00. This adjustment by BTIG analysts suggests a more optimistic outlook for the company's stock performance. The Oncology Institute is traded on the NASDAQ under the ticker

Tone
Positive 68/100
Event
Analyst action
Published
10 Jul 2026 00:10
Source
Moomoo
Investing.com Direct company coverage

BTIG raises Oncology Institute stock price target to $9 on debt refinancing

BTIG has increased its price target for The Oncology Institute (NASDAQ:TOI) to $9.00 from $8.00, maintaining a Buy rating after the company announced it refinanced its $86 million senior secured convertible note. The refinancing involved a new $75 million term loan from OrbiMed a

Tone
Positive 72/100
Event
Balance sheet
Published
09 Jul 2026 22:10
Source
Investing.com
Stock Titan Direct company coverage

Oncology Institute (TOI) director receives 17,185-share fully vested RSU grant

Oncology Institute (TOI) director Kimberly Jo Tzoumakas received a fully vested Restricted Stock Unit (RSU) grant of 17,185 shares of common stock on July 7, 2026, as reported in a Form 4 SEC filing. The grant was recorded at a price of $0.00 per share and is considered compensat

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:59
Source
Stock Titan
Stock Titan Direct company coverage

Oncology Institute (TOI) director receives 25,833 fully vested RSU shares

Oncology Institute (TOI) director Mark Stolper reported receiving 25,833 fully vested Restricted Stock Units (RSU) shares of common stock on July 7, 2026, as an equity compensation grant. This transaction, classified as a non-cash award at $0.00 per share, increases Stolper's dir

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:59
Source
Stock Titan
Stock Titan Direct company coverage

Oncology Institute (NASDAQ: TOI) adds $75M OrbiMed loan in major refi

The Oncology Institute (NASDAQ: TOI) has completed a major refinancing deal, securing a new $75 million term loan from OrbiMed Opportunities. This new loan, maturing in 2031, was used along with $11 million in cash to repay their existing $86 million 4% senior secured convertible

Tone
Neutral 50/100
Event
Balance sheet
Published
07 Jul 2026 21:01
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of The Oncology Institute, Inc. – NASDAQ:TOI

This article provides the enterprise value to forward revenue for The Oncology Institute, Inc., traded on NASDAQ under the ticker TOI. It is presented in the context of financial data available on TradingView, covering market information and financial performance indicators for t

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 14:41
Source
TradingView
Investing.com Direct company coverage

Oncology Institute refinances $86m debt with OrbiMed

The Oncology Institute (NASDAQ:TOI) has refinanced its $86 million senior secured convertible note with Deerfield Partners through a new $75 million term loan from OrbiMed and $11 million in cash. This refinancing increases liquidity, improves operating flexibility, and extends d

Tone
Positive 77/100
Event
Balance sheet
Published
07 Jul 2026 13:41
Source
Investing.com
GlobeNewswire Direct company coverage

The Oncology Institute Completes Strategic Refinancing with

The Oncology Institute (TOI) announced the completion of a strategic refinancing with OrbiMed, repaying an $86 million senior secured convertible note from Deerfield Partners. This new financing arrangement, including a $75 million term loan from OrbiMed, is designed to enhance T

Tone
Positive 76/100
Event
Balance sheet
Published
07 Jul 2026 12:41
Source
GlobeNewswire
GeneOnline Direct company coverage

The Oncology Institute Refinances $86 Million Debt Through OrbiMed Agreement

The Oncology Institute (TOI) has completed a strategic agreement with OrbiMed to refinance its outstanding $86 million convertible note previously held by Deerfield. This transaction addresses TOI's existing debt and aims to improve its liquidity and balance sheet structure. The

Tone
Positive 72/100
Event
Balance sheet
Published
07 Jul 2026 12:41
Source
GeneOnline
Stock Titan Direct company coverage

Oncology Institute swaps $86M debt for OrbiMed financing

The Oncology Institute (NASDAQ: TOI) has completed a strategic debt refinancing, repaying its $86 million senior secured convertible note with Deerfield Partners. This was achieved through a new $75 million term loan from OrbiMed, set to mature in 2031, plus approximately $11 mil

Tone
Positive 70/100
Event
Balance sheet
Published
07 Jul 2026 12:41
Source
Stock Titan
Insider Monkey Direct company coverage

Why Oncology Institute’s (TOI) Analyst Upgrades Put Its Community Cancer Care Growth Story in Focus

The Oncology Institute, Inc. (NASDAQ:TOI) has received analyst upgrades, highlighting confidence in its community-based cancer care growth story. Needham raised its price target to $7 and BTIG to $8, both maintaining Buy ratings. While acknowledging investment risks for TOI, the

Tone
Positive 78/100
Event
Analyst action
Published
07 Jul 2026 03:43
Source
Insider Monkey
Investing.com Canada Direct company coverage

Lake Street initiates Oncology Institute stock coverage with buy rating By Investing.com

Lake Street has initiated coverage on The Oncology Institute Inc. (NASDAQ:TOI) with a Buy rating and a $10.00 price target, citing significant growth in oncology drug spending. The company recently exceeded Q1 2026 earnings expectations, and another firm, Needham, also raised its

Tone
Positive 75/100
Event
Analyst action
Published
06 Jul 2026 14:11
Source
Investing.com Canada
TradingView Direct company coverage

Enterprise value to EBIT forward of The Oncology Institute, Inc. – NASDAQ:TOI

The article focuses on the enterprise value to EBIT forward for The Oncology Institute, Inc., traded under the ticker NASDAQ:TOI. It indicates that the company's financials are available for review on TradingView, a platform providing market data and financial tools. The content

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 14:11
Source
TradingView
Investing.com Direct company coverage

Lake Street initiates Oncology Institute stock coverage with buy rating

Lake Street has initiated coverage on The Oncology Institute Inc. (NASDAQ:TOI) with a Buy rating and a $10.00 price target, citing significant growth in oral oncolytics spending. The stock has shown strong performance, and analysts maintain a Strong Buy consensus. This comes afte

Tone
Positive 73/100
Event
Analyst action
Published
06 Jul 2026 13:40
Source
Investing.com
Finviz Direct company coverage

TOI - Oncology Institute Inc Options

This article provides a comprehensive overview of Oncology Institute Inc. (TOI) stock, detailing its financial performance, key ratios, ownership data, and stock performance metrics. It covers important financial figures like market cap, income, sales, and various P/E and EV rati

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 09:09
Source
Finviz
Insider Monkey Direct company coverage

5 Best Medical Care Facilities Stocks to Buy According to Analysts

The article identifies The Oncology Institute, Inc. (NASDAQ:TOI) as one of the best medical care facilities stocks to buy, based on analyst recommendations. Analysts project significant upside for TOI, with recent price target increases from Needham and BTIG suggesting confidence

Tone
Positive 69/100
Event
Analyst action
Published
04 Jul 2026 17:22
Source
Insider Monkey
TradingView Direct company coverage

Price to earnings forward of The Oncology Institute, Inc. – NASDAQ:TOI

This article provides financial information for The Oncology Institute, Inc. (NASDAQ: TOI) on TradingView. It specifically highlights the company's "Price to earnings forward" metric, displayed within the financial section of its profile. The page indicates that the market is cur

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 23:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of The Oncology Institute, Inc. – NASDAQ:TOI

This article provides financial information for The Oncology Institute, Inc. (NASDAQ: TOI). Specifically, it highlights the enterprise value to EBITDA forward metric for the company. The data is presented within a financial platform, likely TradingView, indicating its use for mar

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 03:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of The Oncology Institute, Inc. – NASDAQ:TOI

This article provides financial information for The Oncology Institute, Inc. (NASDAQ: TOI), specifically its price-to-sales forward ratio. It notes that the market is closed and there are no trades, indicating a snapshot of a financial metric rather than a news update on recent s

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 02:40
Source
TradingView